Literature DB >> 12777268

Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia.

Sarah M Clinton1, Vahram Haroutunian, Kenneth L Davis, James H Meador-Woodruff.   

Abstract

OBJECTIVE: NMDA receptor dysfunction has been implicated in the pathophysiology of schizophrenia. The NMDA receptor is a multimeric ligand-gated ion channel, and the obligate NR(1) subunit is expressed as one of eight isoforms due to the alternative splicing of exons 5, 21, and 22. Alternative splicing of NR(1) subunits modulates receptor function by influencing the association of NR(1) with other NMDA receptor subunits and myriad intracellular molecules, such as the postsynaptic density family of proteins that target NMDA receptors to the synaptic membrane and couple it to numerous signal transduction enzymes. Recently, the authors reported that the NMDA receptor subunits NR(1) and NR(2C) are abnormally expressed in the thalamus in schizophrenia. They hypothesized that this reduction is associated with specific NR(1) isoforms and that NMDA receptor-related postsynaptic density proteins are abnormally expressed.
METHOD: Using in situ hybridization, the authors examined expression of the transcripts encoding NR(1) isoforms containing exons 5, 21, or 22, and the NMDA receptor-related postsynaptic density proteins NF-L, PSD93, PSD95, and SAP102.
RESULTS: Reduced NR(1) subunit transcript expression was restricted to exon 22-containing isoforms. Increased expression of the NMDA receptor-associated postsynaptic density proteins NF-L, PSD95, and SAP102 was also detected in the thalamus of subjects with schizophrenia.
CONCLUSIONS: These data support the hypothesis of glutamatergic abnormalities in schizophrenia and suggest that glutamatergic dysfunction may occur not only at the level of receptor expression but also within intracellular pathways associated with glutamate receptor-associated signal transduction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12777268     DOI: 10.1176/appi.ajp.160.6.1100

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  39 in total

Review 1.  MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.

Authors:  Andrea de Bartolomeis; Felice Iasevoli; Carmine Tomasetti; Elisabetta F Buonaguro
Journal:  Mol Neurobiol       Date:  2014-11-14       Impact factor: 5.590

Review 2.  Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches.

Authors:  Andrea de Bartolomeis; Gianmarco Latte; Carmine Tomasetti; Felice Iasevoli
Journal:  Mol Neurobiol       Date:  2013-09-03       Impact factor: 5.590

3.  Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder.

Authors:  Robert E McCullumsmith; Lars V Kristiansen; Monica Beneyto; Elizabeth Scarr; Brian Dean; James H Meador-Woodruff
Journal:  Brain Res       Date:  2006-11-17       Impact factor: 3.252

4.  Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia.

Authors:  Deborah Bauer; Daya Gupta; Vahram Harotunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2008-08-03       Impact factor: 4.939

5.  Abnormal partitioning of hexokinase 1 suggests disruption of a glutamate transport protein complex in schizophrenia.

Authors:  Dan Shan; Daniel Mount; Stephen Moore; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2014-02-21       Impact factor: 4.939

6.  Gene expression of glutamate metabolizing enzymes in the hippocampal formation in human temporal lobe epilepsy.

Authors:  Tore Eid; Tih-Shih W Lee; Yue Wang; Edgar Perez; Edgar Peréz; Jana Drummond; Fredrik Lauritzen; Linda H Bergersen; James H Meador-Woodruff; Dennis D Spencer; Nihal C de Lanerolle; Robert E McCullumsmith
Journal:  Epilepsia       Date:  2012-11-13       Impact factor: 5.864

Review 7.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

8.  Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia.

Authors:  Amy E Steffek; Robert E McCullumsmith; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Schizophr Res       Date:  2008-06-17       Impact factor: 4.939

9.  Dysbindin regulates hippocampal LTP by controlling NMDA receptor surface expression.

Authors:  Tina Tze-Tsang Tang; Feng Yang; Bo-Shiun Chen; Yuan Lu; Yuanyuan Ji; Katherine W Roche; Bai Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-01       Impact factor: 11.205

10.  Genetic and functional analysis of the DLG4 gene encoding the post-synaptic density protein 95 in schizophrenia.

Authors:  Min-Chih Cheng; Chao-Lin Lu; Sy-Ueng Luu; Ho-Min Tsai; Shih-Hsin Hsu; Tzu-Ting Chen; Chia-Hsiang Chen
Journal:  PLoS One       Date:  2010-12-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.